 Number 1

bleeding was infrequent in both groups. A second systematic review and meta-analysis included seventeen
studies and 6862 patients with SVT and conÔ¨Årmed that
fondaparinux achieved the lowest rate of progression to
DVT and PE without conclusions about other treatment
due to low quality evidence.35 In the Surprise study, patients with SVT and one or more risk factors for VTE were
randomized to 45 days